CRIS Current Research Information System

CECI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.105
AS - Asia 3.992
EU - Europa 3.326
AF - Africa 310
SA - Sud America 243
OC - Oceania 7
AN - Antartide 1
Totale 12.984
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.057
SG - Singapore 1.101
CN - Cina 1.048
VN - Vietnam 1.002
GB - Regno Unito 901
IT - Italia 570
DE - Germania 448
SE - Svezia 419
HK - Hong Kong 361
RU - Federazione Russa 226
IN - India 216
BR - Brasile 181
FR - Francia 146
IE - Irlanda 140
ZA - Sudafrica 91
NL - Olanda 88
TG - Togo 86
FI - Finlandia 75
EE - Estonia 74
KR - Corea 74
CI - Costa d'Avorio 69
JO - Giordania 62
CH - Svizzera 53
UA - Ucraina 45
BG - Bulgaria 40
CA - Canada 36
AR - Argentina 34
SC - Seychelles 30
JP - Giappone 28
IR - Iran 27
BE - Belgio 26
NG - Nigeria 22
ID - Indonesia 20
PL - Polonia 17
ES - Italia 15
EC - Ecuador 14
AT - Austria 13
BD - Bangladesh 13
MX - Messico 9
RO - Romania 8
CL - Cile 7
AU - Australia 6
IQ - Iraq 5
LT - Lituania 5
EG - Egitto 4
KZ - Kazakistan 4
MY - Malesia 4
TR - Turchia 4
CZ - Repubblica Ceca 3
GR - Grecia 3
PT - Portogallo 3
RS - Serbia 3
SA - Arabia Saudita 3
TH - Thailandia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
DK - Danimarca 2
KG - Kirghizistan 2
LB - Libano 2
PK - Pakistan 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AQ - Antartide 1
BY - Bielorussia 1
CM - Camerun 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GA - Gabon 1
HR - Croazia 1
KE - Kenya 1
LK - Sri Lanka 1
MA - Marocco 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PS - Palestinian Territory 1
PY - Paraguay 1
RE - Reunion 1
SV - El Salvador 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 12.984
Salva come PNG Salva come JPEG
Città #
Southend 826
Singapore 790
Fairfield 605
Ashburn 591
Chandler 405
Hong Kong 361
Seattle 272
Santa Clara 266
Wilmington 266
Houston 264
Woodbridge 258
Cambridge 229
Princeton 184
Hefei 161
Beijing 155
Dublin 140
Ann Arbor 133
Dong Ket 124
Bologna 118
Boardman 106
Westminster 89
Lomé 86
Ho Chi Minh City 81
Hanoi 75
Los Angeles 74
Nanjing 73
Seoul 73
Berlin 70
Abidjan 69
Padova 68
Amman 62
Helsinki 61
Redondo Beach 51
New York 47
Bern 45
Milan 41
Shenyang 40
Jinan 39
Munich 39
Dallas 37
Sofia 36
Florence 34
Buffalo 33
Saint Petersburg 33
Turin 31
San Diego 30
Changsha 29
Medford 29
Hebei 27
Nanchang 27
Bremen 25
Brussels 24
Redwood City 23
Tokyo 22
Toronto 22
Tianjin 21
Abeokuta 20
Guangzhou 20
Rome 20
Frankfurt am Main 19
Nuremberg 19
Zhengzhou 19
Bengaluru 17
London 15
Norwalk 15
Phoenix 15
Dearborn 14
São Paulo 14
Yubileyny 14
Brooklyn 13
Falkenstein 13
Falls Church 12
Haiphong 12
Jiaxing 12
Shanghai 12
Chicago 11
Taiyuan 11
Taizhou 11
Des Moines 10
Jakarta 10
Tongling 10
Da Nang 9
Hangzhou 9
Johannesburg 9
Warsaw 9
Biên Hòa 8
Fuzhou 8
Haikou 8
Kuban 8
Moscow 8
Ottawa 8
Quận Bình Thạnh 8
Redmond 8
Venezia 8
Vienna 8
Dongguan 7
Guayaquil 7
Lappeenranta 7
Lauterbourg 7
Olalla 7
Totale 8.429
Salva come PNG Salva come JPEG
Nome #
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 243
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence 237
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 215
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 193
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 192
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 190
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 186
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 184
68Ga-PSMA PET/CT for restaging prostate cancer after definitive therapy: Results of a prospective single-center trial 183
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 182
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 181
11C-Choline PET/CT for Restaging of Bladder Cancer 179
68Ga-PSMA PET/CT in prostate cancer 178
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and midterm follow-up 176
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 175
How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? 169
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 167
18F-FACBC PET/CT in comparison to 11c-choline for the detection of prostate cancer relapse after radical prostatectomy: A perspective study in 50 patients 164
18f-fdg pet/ct for restaging gastric cancer after surgical resection 163
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 161
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 160
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 157
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 157
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 156
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 154
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 150
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 147
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment 143
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 143
18F-FACBC PET/CT VS. 11C-CHOLINE FOR THE DETECTION OF PROSTATE CANCER RELAPSE AFTER RADICAL TREATMENT 143
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 142
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 138
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. 138
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 135
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. 134
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 134
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 134
New radiopharmaceutical markers for metabolism and receptor 133
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 133
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 131
PET/CT and prostate cancer 130
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: Impact on salvage radiotherapy planning 130
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. 130
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT IN COMPARISON WITH CONTRASTENHANCED CT IN THE PREOPERATIVE LYMPH-NODE STAGING OF BLADDER CANCER USING THE PATHOLOGICAL SPECIMENS AS REFERENCE STANDARD 129
IL RUOLO DELLA 11C-COLINA PET/CT IN PAZIENTI CON RECIDIVA BIOCHIMICA DOPO PROSTATECTOMIA RADICALE E CARCINOMA PROSTATICO ORMONO-RESISTENTE SOTTOPOSTI A TERAPIA DI DEPRIVAZIONE ANDROGENICA 129
Role of 11C-Choline PET/CT in androgen sensitive prostate cancer patients treated with intermittent ADT: A sequential PET/CT study after therapy interruption 127
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 126
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 126
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. 125
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 124
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT COMPARED TO CONTRASTENHANCED CT IN THE POSTOPERATIVE RESTAGING OF RECURRENT BLADDER CANCER: ANALYSIS OF 20 CONSECUTIVE PATIENTS 123
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 122
PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications 120
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. 120
null 119
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. 117
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. 114
null 113
PREOPERATIVE 11C-CHOLINE PET-CT IN INTERMEDIATE, HIGH RISK AND VERY HIGH RISK PROSTATE CANCER PATIENTS: IS THERE STILL ANY ROOM LEFT FOR IT? 112
Clinical impact of 11C-Choline PET/CT in recurrent prostate cancer patients after radical therapy: Which is the real impact on treatment decisions? 112
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: preliminary results 112
Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. 111
New aspects of molecular imaging in prostate cancer. 109
Role of 18F-FDG PET/CT in the restaging of patients affected by clear cell renal carcinoma 108
PET/CT in prostate cancer 108
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. 107
Ga-68-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels< 2 ng/mL 107
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial 107
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 106
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 106
Yttrium 90 Intra Arterial Radioembolization Therapy of Unresectable Intrahepatic Cholangiocarcinoma: 5 Year Experience at a Single Center 106
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis 105
Detection of sarcomatoid lung metastasis with 68GA-PSMA PET/CT in a patient with prostate cancer 105
Comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence 104
Molecular Imaging and Precision Medicine in Prostate Cancer 103
68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report 102
Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings. 102
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 101
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68 Ga-PSMA-11 PET/CT 101
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml 100
Therapy assessment in prostate cancer using choline and PSMA PET/CT. 99
Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. 99
Reply: Comparison of68Ga-PSMA-11 and18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way 98
Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications 97
A new type of prostate cancer imaging. Will64CuCl2PET/CT flourish or vanish? 96
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer 94
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. 93
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals 90
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 87
The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? 87
Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders 86
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. 81
Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence 79
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy 75
New radiopharmaceutical Markers for Matebolism and receptor 74
null 73
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply 73
PSMA-PET/CT imaging in prostate cancer: why and when 72
A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study 66
SEM, TEM, and IHC Analysis of the Sinus Node and Its Implications for the Cardiac Conduction System 65
Totale 12.822
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.336
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021729 0 0 0 0 0 46 23 60 151 43 35 371
2021/20221.983 554 58 97 126 170 78 49 114 62 59 357 259
2022/20231.949 172 288 112 254 115 133 50 103 386 89 145 102
2023/2024555 75 85 26 54 39 90 30 34 22 42 29 29
2024/20252.352 114 344 173 187 430 151 135 49 24 123 110 512
2025/20262.292 491 404 426 366 583 22 0 0 0 0 0 0
Totale 13.265